Related Experiment Video
Updated: Feb 16, 2026

Author Spotlight: Development of a Minimally Invasive Large-Animal Model for Reliable and Reproducible Cardiovascular Research
Published on: October 20, 2023
Aortic Stenosis, Aortic Regurgitation and Arterial Hypertension
V Katsi1, G Georgiopoulos1, D Oikonomou2
1First Department of Cardiology, 'Hippokration' Hospital, University of Athens, Medical School, Athens, Greece.
Background:
Hypertension (HT) is an important risk factor for cardiovascular disease and might precipitate pathology of the aortic valve.
Objective:
To investigate the association of HT with aortic dysfunction (including both aortic regurgitation and stenosis) and the impact of antihypertensive treatment on the natural course of underlying aortic disease.
Methods:
We performed a systematic review of the literature for all relevant articles assessing the correlation between HT and phenotype of aortic disease.
Results:
Co-existence of HT with aortic stenosis and aortic regurgitation is highly prevalent in hypertensive patients and predicts a worse prognosis. Certain antihypertensive agents may improve haemodynamic parameters (aortic jet velocity, aortic regurgitation volume) and remodeling of the left ventricle, but there is no strong evidence of benefit regarding clinical outcomes. Renin-angiotensin system inhibitors, among other vasodilators, are well-tolerated in aortic stenosis.
Conclusion:
Several lines of evidence support a detrimental association between HT and aortic valve disease. Therefore, HT should be promptly treated in aortic valvulopathy. Despite conventional wisdom, specific vasodilators can be used with caution in aortic stenosis.
Related Concept Videos
Aortic Regurgitation I: Introduction
Aortic Regurgitation IV: Nursing Management
Aortic Regurgitation III: Medical Management
Aortic Regurgitation II: Clinical Features and Diagnostic Tests
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

